- Home
- MPU vs ATRA Comparison
MPU vs ATRA Comparison
Compare MPU & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- ATRA
- Stock Information
- Founded
- MPU 1989
- ATRA 2012
- Country
- MPU Singapore
- ATRA United States
- Employees
- MPU N/A
- ATRA N/A
- Industry
- MPU Transportation Services
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPU Consumer Discretionary
- ATRA Health Care
- Exchange
- MPU Nasdaq
- ATRA Nasdaq
- Market Cap
- MPU 43.5M
- ATRA 48.5M
- IPO Year
- MPU 1998
- ATRA 2014
- Fundamental
- Price
- MPU $0.90
- ATRA $7.11
- Analyst Decision
- MPU
- ATRA Buy
- Analyst Count
- MPU 0
- ATRA 6
- Target Price
- MPU N/A
- ATRA $25.70
- AVG Volume (30 Days)
- MPU 113.4K
- ATRA 178.5K
- Earning Date
- MPU 03-17-2025
- ATRA 03-27-2025
- Dividend Yield
- MPU N/A
- ATRA N/A
- EPS Growth
- MPU N/A
- ATRA N/A
- EPS
- MPU N/A
- ATRA N/A
- Revenue
- MPU $26,001,000.00
- ATRA $100,439,000.00
- Revenue This Year
- MPU N/A
- ATRA $1,281.31
- Revenue Next Year
- MPU N/A
- ATRA N/A
- P/E Ratio
- MPU N/A
- ATRA N/A
- Revenue Growth
- MPU 1444400.00
- ATRA 2111.34
- 52 Week Low
- MPU $0.77
- ATRA $5.40
- 52 Week High
- MPU $3.33
- ATRA $23.45
- Technical
- Relative Strength Index (RSI)
- MPU 37.01
- ATRA 37.35
- Support Level
- MPU $0.88
- ATRA $8.05
- Resistance Level
- MPU $1.10
- ATRA $9.05
- Average True Range (ATR)
- MPU 0.14
- ATRA 0.85
- MACD
- MPU 0.01
- ATRA -0.06
- Stochastic Oscillator
- MPU 15.38
- ATRA 2.23
About MPU Mega Matrix Corp.
Mega Matrix Inc formerly Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).